Vosburg SK, et al. - Researchers performed this retrospective cohort study to assess the abuse liability of tapentadol Active Pharmaceutical Ingredient (API) is compared to those of other Scheduled opioids. Findings revealed a low but present public health burden related to tapentadol. Compared to all other opioids examined, event rates of abuse per population-level denominators were markedly lower. However, when adjusted for drug availability, event rates of abuse were lower than most CII opioids studied, but were not the lowest. Findings justified disentangling these two sets of findings further by examining various opioid formulations, such as extended-release and the role of abuse-deterrent formulations.